首页> 外文OA文献 >Inhibition of HIV-1 Infection and Replication by Enhancing Viral Incorporation of Innate Anti-HIV-1 Protein A3G: A NON-PATHOGENIC Nef MUTANT-BASED ANTI-HIV STRATEGY*
【2h】

Inhibition of HIV-1 Infection and Replication by Enhancing Viral Incorporation of Innate Anti-HIV-1 Protein A3G: A NON-PATHOGENIC Nef MUTANT-BASED ANTI-HIV STRATEGY*

机译:通过增强病毒抑制HIV-1感染和复制 天然抗HIV-1蛋白A3G的合并:一个非致病性Nef。 基于突变的抗艾滋病毒 战略*

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

APOBEC3G (A3G) is a cellular protein that has been identified as an innate anti-human immunodeficiency virus type 1 (HIV-1) factor. One of the major functions of HIV-1 virion infectivity protein (Vif) protein is to target A3G for ubiquitination/proteasome-mediated degradation and, as a result, evade the host innate defense mechanism. Thus, we wished to devise a strategy to restore the anti-HIV activity of A3G by actively targeting it into HIV-1 virions and countering HIV-1 Vif-targeted degradation. In the current study we performed a series of proof-of-concept experiments for this strategy using as a delivery vehicle of A3G, a derivate of non-pathogenic Nef mutant Nef7 that is capable of being efficiently incorporated into HIV-1 virions. We demonstrate that the Nef7.A3G fusion protein retains several important properties of Nef7; that is, the higher virion incorporation efficiency, no PAK-2 (p21-activated kinase 2) activation, and no CD4 and major histocompatibility complex I down-regulation. Meanwhile, we show that virion incorporated Nef7.A3G possesses the anti-HIV infectivity function of A3G. Moreover, we show that virus-like particle-mediated inverse fusion delivery of Nef7.A3G into HIV-infected CD4+ T lymphocytes leads to potent inhibition of HIV-1 replication in these cells. Taken together, these results indicate that Nef7.A3G can effectively restrict HIV infection and replication by restoring the virion incorporation of A3G, even in the presence of Vif.
机译:APOBEC3G(A3G)是一种细胞蛋白,已被确定为先天性抗人免疫缺陷病毒1型(HIV-1)因子。 HIV-1病毒体感染性蛋白(Vif)的主要功能之一是将A3G靶向于泛素化/蛋白酶体介导的降解,从而逃避了宿主的先天防御机制。因此,我们希望设计一种策略,通过积极地将A3G靶向HIV-1病毒颗粒并对抗HIV-1 Vif靶向的降解来恢复其抗HIV活性。在当前的研究中,我们使用A3G的传递载体进行了一系列针对该策略的概念验证实验,A3G是能够有效整合到HIV-1病毒体中的非致病性Nef突变体Nef7的衍生物。我们证明Nef7.A3G融合蛋白保留了Nef7的几个重要属性;也就是说,更高的病毒体掺入效率,没有PAK-2(p21激活的激酶2)激活,并且没有CD4和主要组织相容性复合物I下调。同时,我们表明掺入Nef7.A3G的病毒粒子具有A3G的抗HIV感染功能。此外,我们显示,Nef7.A3G病毒样颗粒介导的反向融合递送到HIV感染的CD4 + T淋巴细胞中,导致这些细胞中HIV-1复制的有效抑制。综上所述,这些结果表明,即使在Vif存在的情况下,Nef7.A3G也可以通过恢复A3G的病毒体掺入来有效地限制HIV感染和复制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号